Novartis is expected to deliver an 11% annual return by 2027, supported by a strong drug pipeline, financials, and strategic cost management. The company reported a 15.1% sales increase and 29% EPS growth in Q4 2024. Shares are undervalued by 11%, offering a 33% cumulative return potential with a 3.5% dividend yield.